Market Overview

Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018

Share:

Jazz Pharmaceuticals to Report 2018 Second Quarter Financial Results on August 7, 2018

PR Newswire

DUBLIN, July 24, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that it will report its 2018 second quarter financial results on Tuesday, August 7, 2018, after the close of the financial markets.  Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EDT/9:30 p.m. IST to discuss second quarter 2018 financial results and provide a business and financial update.

Interested parties may access the live audio webcast via the Investors section of the Jazz Pharmaceuticals website at http://www.jazzpharmaceuticals.com.  Please connect to the website prior to the start of the conference call to ensure adequate time for any software downloads that may be necessary to listen to the webcast.  A replay of the webcast will be archived on the website for at least one week.

Audio webcast/conference call:
U.S. Dial-In Number:  +1 855 353 7924
International Dial-In Number: +1 503 343 6056
Passcode: 4989706

A replay of the conference call will be available through August 14, 2018 and accessible through one of the following telephone numbers, using the passcode below:

Replay U.S. Dial-In Number: +1 855 859 2056
Replay International Dial-In Number:  +1 404 537 3406
Passcode: 4989706

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is an international biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing meaningful products that address unmet medical needs.  The company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.  In these areas, Jazz Pharmaceuticals markets Xyrem® (sodium oxybate) oral solution, Erwinaze® (asparaginase Erwinia chrysanthemi), Defitelio® (defibrotide sodium) and Vyxeos® (daunorubicin and cytarabine) liposome for injection in the U.S. and markets Erwinase® and Defitelio® (defibrotide) in countries outside the U.S.  For country-specific product information, please visit http://www.jazzpharmaceuticals.com/products.  For more information, please visit http://www.jazzpharmaceuticals.com/ and follow us on Twitter at @JazzPharma.

Jazz Pharmaceuticals Logo (PRNewsFoto/Jazz Pharmaceuticals plc) (PRNewsFoto/Jazz Pharmaceuticals plc)

 

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2018-second-quarter-financial-results-on-august-7-2018-300685803.html

SOURCE Jazz Pharmaceuticals plc

View Comments and Join the Discussion!